Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Sangamo Therapeutics partners with Genentech for genomic medicines development

Dec 15, 2024•over 1 year ago

Contract Type

partnership

BrisbaneBiotechnologyHealth CareGeneticsTherapeutics

Description

Sangamo Therapeutics has entered a global license agreement with Genentech to develop genomic medicines for neurodegenerative diseases, which focuses on the tau gene related to Alzheimer's disease and other tauopathies. This partnership includes a $50 million upfront payment and potential milestone payments of up to $1.9 billion, extending Sangamo's financial runway into the first quarter of 2025.

Company Information

Company

Sangamo Therapeutics

Location

Brisbane, California, United States

About

Sangamo Therapeutics uses science to develop transformative medicines for patients with serious genetic diseases. As pioneers in gene-based therapeutic development, the company’s scientists lead in discovery, research, and innovation, including conducting the first-ever in vivo human genome editing studies now underway in clinical trials.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Sangamo Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.